- $132.52m
- $29.27m
- $27.86m
- 54
- 45
- 58
- 52
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.41 | ||
| Price to Tang. Book | 2.41 | ||
| Price to Free Cashflow | 2.68 | ||
| Price to Sales | 4.76 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -15.7% | ||
| Return on Equity | -23.63% | ||
| Operating Margin | -53.44% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 2 | 6 | 7.5 | 33.46 | 27.86 | 30.54 | 39.21 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.
Directors
- Paul Sekhri NEC (63)
- Anat Cohen-Dayag PRE (54)
- Ari Krashin CFO (48)
- Henry Adewoye SVP (56)
- Oliver Froescheis SVP (55)
- Zurit Levine SVP (53)
- Yaron Turpaz SVP (50)
- Jean-Pierre Bizzari IND (66)
- Gilead Halevy IND (54)
- Kinneret Livnat Savitsky IND (54)
- Eran Perry IND (50)
- Sanford Zweifach IND (64)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- February 10th, 1993
- Public Since
- August 1st, 2000
- No. of Shareholders
- 35
- No. of Employees
- 74
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 89,541,246
- Address
- Azrieli Center, 26 Harokmim St., Bldg D, HOLON, 5885849
- Web
- https://cgen.com/
- Phone
- +972 37658585
- Contact
- Yvonne Naughton
- Auditors
- Kost, Forer, Gabbay & Kasierer
Upcoming Events for CGEN
Q2 2025 Compugen Ltd Earnings Release
Similar to CGEN
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the Compugen share price?
As of Today at 20:02 UTC, shares in Compugen are trading at $1.48. This share price information is delayed by 15 minutes.
How has the Compugen share price performed this year?
Shares in Compugen last closed at $1.48 and the price had moved by -31.48% over the past 365 days. In terms of relative price strength the Compugen share price has underperformed the S&P500 Index by -38.22% over the past year.
What are the analyst and broker recommendations for Compugen?
The overall consensus recommendation for Compugen is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Compugen dividend yield?
Compugen does not currently pay a dividend.
Does Compugen pay a dividend?
Compugen does not currently pay a dividend.
When does Compugen next pay dividends?
Compugen does not currently pay a dividend.
How do I buy Compugen shares?
To buy shares in Compugen you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Compugen?
As of the previous close price of $1.48, shares in Compugen had a market capitalisation of $132.52m.
Where are Compugen shares listed?
Here are the trading details for Compugen:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: CGEN
What kind of share is Compugen?
Based on an overall assessment of its quality, value and momentum Compugen is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Compugen share price forecast for 2025?
The analyst consensus target price for shares in Compugen is $4.75. That is 220.95% above the last closing price of $1.48.
Analysts covering Compugen currently have a consensus Earnings Per Share (EPS) forecast of -$0.12 for the next financial year.
Find out moreWhat is the trend in the Compugen share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Compugen. Over the past six months, its share price has underperformed the S&P500 Index by -13.05%.
As of the last closing price of $1.48, shares in Compugen were trading -15.67% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Compugen PE Ratio?
The Compugen PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.48.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Compugen?
Compugen's management team is headed by:
- Paul Sekhri - NEC
- Anat Cohen-Dayag - PRE
- Ari Krashin - CFO
- Henry Adewoye - SVP
- Oliver Froescheis - SVP
- Zurit Levine - SVP
- Yaron Turpaz - SVP
- Jean-Pierre Bizzari - IND
- Gilead Halevy - IND
- Kinneret Livnat Savitsky - IND
- Eran Perry - IND
- Sanford Zweifach - IND